Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Investigators used 3-dimensional quantitative computed tomography to more accurately assess patients’ bone mineral density.

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

Diabetes poses a significant risk to bone health, leading to decreased bone mineral density and increased fracture ...

Osteoporosis affects one in five men and one-third of women over 50 globally. Credit: Pormezz via Shutterstock. · Clinical ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Diabetes significantly increases the risk of bone diseases like osteoporosis, leading to fractures even with normal bone ...

Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...